A double-blind study of the effect of three beta-adrenoceptor blocking drugs (betablockers) on exercise muscle blood flow (MBF) in 14 normotensive volunteers was carried out. MBF was measured by the xenon-133 clearance technique. MBF was not altered by placebo, sotalol or labetalol. Atenolol significantly reduced MBF compared with placebo, sotalol and labetalol.
Introduction
Beta-blockers are widely used for treatment of hypertension and angina pectoris. Peripheral blood flow may be significantly reduced by many of these drugs (McSorley & Warren, 1978; Vale et al., 1977; Rees, 1979; Gokal et al., 1979) . Both selective and nonselective beta-blockers reduce muscle blood flow (MBF), but our studies suggest that partial agonist activity may confer partial protection against this unwanted side effect (Smith & Warren, 1982) . In patients with intermittent claudication MBF during exercise was shown to fall by about 30% after two weeks treatment with propranolol, pindolol and atenolol (Smith & Warren, 1981) . We have examined the acute effects of two beta-blockers with additional properties which suggest that they may have less adverse effects on MBF. Labetalol has an alphaadrenoceptor blocking action which may ameliorate the reduction in MBF which follows pure beta blockade. Sotalol may have less negative inotropic effect on the heart than other beta-blockers and thus may have a smaller effect on peripheral circulation (Brooks et al., 1970) . We have compared the effects on MBF of labetalol, sotalol, atenolol and placebo.
Patients and methods
Fourteen healthy normotensive non-smoking male volunteers were studied: age 35 (± 5.8) years, weight 73.4 (± 7.7) kg. We studied the effects of a single oral dose of atenolol 100 mg, labetalol 200 mg, sotalol 160 mg or placebo (ascorbic acid 50 mg) on heart rate, blood pressure and MBF before and 2, 4, and 6 hours after dosing. These doses were chosen as standard doses used for treatment of hypertension. The drugs were given in random order on different study days, in opaque gelatine capsules ofidentical appearance, with 200 ml of water. Different drugs were studied on separate occasions at intervals of not less than 7 days. The subjects were rested supine for a period of 15 minutes and blood pressure and heart rate were recorded every 3 minutes using Sentron® automatic blood monitor (CR Bard Inc., Illinois, USA). Xenon-133 (0.1 mCi in 0.1 ml of normal saline) was injected into the tibialis anterior muscle 10cm below the tibial tuberosity and 2 cm lateral to the anterior edge of the tibia, using a fine needle (25 gauge 16mm), with the patient resting. A cadmium telluride detector was strapped to the skin over the site of the injection and radioactivity measured using a small solidstate counter with memory (Memolog, Vertec Scientific, Slough, Bucks, England). The exercise was standardized to 5 minutes walking on a treadmill at 3 km/h against a 10% gradient. Immediately at the end ofexercise heart rate and blood pressure were recorded standing. MBF was calculated from the slope of the xenon clearance curve during exercise as described earlier (Smith et al., 1981; Lassen et al., 1964; Clausen & Lassen, 1971 ). Ten ml of blood was taken just before exercise during each of the four observation periods for estimation of drug concentration. Calculated MBF is expressed as ml/100 g/min. Values were compared by the Students' paired t test. 
Results
Supine heart rate and mean arterial pressure measurements are shown in Table I , post-exercise values in Table II , and plasma levels of the drugs in Table III . There was a significant fall in heart rate after sotalol and atenolol, but not after labetalol or placebo. Mean arterial pressure, systolic and diastolic blood pressures fell significantly after all the three active drugs, when compared with placebo. For the sake of brevity we have omitted systolic and diastolic blood pressures. There were no significant differences in exercise MBF (Table IV) at time 0 on the four study days, measurements being in the range of 18.7-20.1 ml/l00 g/min. After administration of sotalol, labetalol and placebo there was no significant change in MBF at 2, 4 or 6 hours, or when the latter three values were averaged. After administration of atenolol the mean exercise MBF fell at 2 hours to 17.2 ml/l00 g/min, remained at that value at 4 hours and fell further at 6 hours to 15.7ml/lOOg/min (P < 0.05). The 6 hour post-atenolol MBF was also significantly less than the corresponding 6 hour postlabetalol value of 20.8 ml/100 g/min (P < 0.05). The average ofthe 2, 4 and 6 hour values after atenolol was 16.7 ml/l00 g/min and this was again significantly less than the baseline value (P < 0.05). Further, when the 2, 4 and 6 hour values were pooled and compared, the post-atenolol MBF was significantly less than that of sotalol (P<0.05), labetalol (P<0.01) and placebo (P<0.01). There were no differences in the corresponding values between sotalol, labetalol and placebo.
Discussion
Hypertension and ischaemic heart disease frequently occur in association with peripheral vascular disease. Beta-blockers are widely used in the treatment of hypertension and angina but their use may often be limited by precipitation or aggravation of peripheral vascular disease. Though peripheral vascular insufficiency has been clearly associated with beta-blockers in contrast to methyl dopa (Marshall et al., 1976) formal measurements ofblood flow have not been well studied. In an attempt to identify beta-blockers without this adverse effect we decided to study the effect on MBF of two agents with unusual properties and compare them with placebo and atenolol. The latter drug has been shown to reduce MBF in normal subjects (Smith & Warren, 1982) and claudicants (Smith & Warren, 1981) , and this effect has been confirmed in this study. All three active drugs produced the expected reduction in blood pressure. Sotalol and atenolol reduced heart rate but labetalol did not. One ofthe mechanisms by which non-selective betablockers may reduce MBF is thought to be unopposed stimulation of alpha-receptors in the presence of beta blockade. Labetalol possesses additional alpha-adrenoceptor blocking actions and this would explain the lack ofeffect ofthis drug on MBF or heart rate. Unlike other beta-blockers labetalol is not known to cause peripheral skin necrosis (Rees, 1979; Gokal et al., 1979) . Indeed, it has been demonstrated that after chronic treatment labetalol preserves finger blood flow better than propranolol but not atenolol, in hypertensive patients without peripheral vascular disease (van der Veur et al., 1985) .
Sotalol is a beta-blocker that has been shown to have Class III anti-arrhythmic properties (Edvardsson et al., 1980) , and may have less effect than other betablockers on cardiac output (Brooks et al., 1970) , though this is disputed (Verniory et al., 1976; Wendelin et al., 1974; Dexter et al., 1974) . Its effect on peripheral vascular disease is not established and our studies suggest that it does not have any adverse effect on MBF. Nevertheless this lack of effect is not clearly explained and merits further investigation.
We conclude that this lack of effect of sotalol and labetalol on muscle blood flow could be of significant benefit to the patient suffering from a combination of peripheral vascular disease and angina or hypertension. 
